|Conditional recommendation based on low-quality evidence; may consider abatacept if the patient prefers IV dosing or in patients with recurrent or serious infections.| |
|10. Switch to an IL-12/23i biologic over tofacitinib (PICO 74)|Low (98â€“100, 105)|
|Conditional recommendation based on low-quality evidence; may consider tofacitinib if the patient prefers an oral therapy.| |